Arch Therapeutics Inc (ARTH)

[Regis999]

So Arch is about to be at a very interesting crossroad. Do they joint venture all 200+- AC5 applications and lock them up with one party? Or do they narrow it to just certain external ones? Don't know the answer but it is a very interesting jigsaw puzzle.

When they sell out do they get any value for the applications that are not being used because of additional testing required?

We know the total additional capital required to rollout cost for Europe and USA is $ 6 to $ 10 million. In the biotech world that is TINY.

Dr. Norchi will not be in his element until Arch is uplisted and shown in all its true colors. He has had 10 years to prepare for this moment. If you listen to his presentations over last couple years they have become more and more polished.

He did 8 presentations in 2015. We are due for one soon.